CA-ADSWIZZ
17.2.2021 12:02:05 CET | Business Wire | Press release
AdsWizz, the leading global technology provider for digital audio advertising solutions, has been certified by the IAB Tech Lab as Open Measurement Software Development Kit (OM SDK) compliant. This is the first time an audio ad-tech provider has had their SDK certified for OM SDK compliance, enabling “audibility” verification of audio ads. With this in place, publishers and advertisers can now know for certain whether an ad was heard or not.
“Advertisers coming from video and display, where standards like this are in place, need validation that their investment in audio is safe,” said Erik Barraud, SVP of Product Management at AdsWizz. “That is why we continue to lead the industry and embrace standards that help us – and all of our partners – give advertisers assurance and peace of mind when it comes to audio advertising.”
AdsWizz’s SDK reaches over 500 million unique devices globally and is used by some of the world’s largest audio publishers, such as TuneIn in the U.S.; Bauer Media and Wireless in the U.K.; M6 and NRJ in France; Crossplan Deutschland Publishers in Germany; ARN, SCA and NZME in Australia and New Zealand. Pandora and SoundCloud adoption are planned for later this year. By enabling audibility verification, not only do advertisers receive certainty that their ad was heard, but they are also able to verify this against the largest footprint of audiences listening to premium audio content.
AdsWizz’s SDK is a versatile piece of technology that powers unique advertising capabilities, such as interactive ad formats. AdsWizz ShakeMe and AdsWizz Voice Ads allow the listener to interact with the ad by shaking their phone or giving a voice response, respectively. The interactive responses can download an app or coupon, take the listener to a website to learn more, deliver directions to a store location, and more.
“The Open Measurement SDK was created to bring transparency and consistency to in-app advertising,” said Shailley Singh, Vice President, Product Management and Global Programs, IAB Tech Lab. “The adoption of the OM SDK by AdsWizz brings the lessons learned in web and display to lay the foundation for open and transparent audio advertising.”
The OM SDK, released by IAB Tech Lab in April 2018, was originally designed to facilitate third-party viewability and verification measurement for ads served to web video and mobile app environments. The recent certification of the AdsWizz SDK uses the recent version 1.3 of the OM SDK that supports audio measurement for the first time, taking the same third-party verification measurement standards and applying them to audio ads for audibility. To classify as an “audible” ad, the audio ad must play for 2 seconds with the player unmuted.
The AdsWizz OM SDK certification by IAB Tech Lab applies globally. AdsWizz SDK 7.2 was released in October 2020 and is available to publishers using the AdsWizz Campaign Manager (AudioServe) in all global markets.
About AdsWizz
AdsWizz has created the end-to-end technology platform that is powering the digital audio advertising ecosystem. AdsWizz is the underlying monetization solution for well-known music platforms, podcasts and broadcasting groups worldwide. Through dynamic ad insertion, advanced programmatic platforms, and innovative audio formats, AdsWizz efficiently connects buyers and sellers for digital audio and podcast advertising. AdsWizz is owned by SiriusXM, and is headquartered in San Mateo, California, with a Technology Development Hub in Bucharest, Romania.
About IAB Tech Lab
Established in 2014, the IAB Technology Laboratory (Tech Lab) is a non-profit consortium that engages a member community globally to develop foundational technology and standards that enable growth and trust in the digital media ecosystem. Comprised of digital publishers, ad technology firms, agencies, marketers, and other member companies, IAB Tech Lab focuses on solutions for brand safety and ad fraud; identity, data, and consumer privacy; ad experiences and measurement; and programmatic effectiveness. Its work includes the OpenRTB real-time bidding protocol, ads.txt anti-fraud specification, Open Measurement SDK for viewability and verification, VAST video specification, and the Project Rearc initiative for privacy-centric addressability. Board members/companies are listed at: https://iabtechlab.com/about-the-iab-tech-lab/tech-lab-leadership/
. For more information, please visit: https://iabtechlab.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom